Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Lung Cancer

  Free Subscription


Articles published in AJR Am J Roentgenol

Retrieve available abstracts of 47 articles:
HTML format



Single Articles


    November 2022
  1. OPTICAN RJ, Chiles C
    Lung Cancer Screening in Never Smokers: Counterpoint-Cannot Identify Which Never Smokers Are at Sufficient Risk to Balance the Potential Harms of Screening.
    AJR Am J Roentgenol. 2022 Nov 2. doi: 10.2214/AJR.22.28644.
    PubMed    


  2. KANNE JP
    Lung Cancer Screening in Never Smokers: Point-Might Reduce Mortality With Comprehensive Risk Assessment and Conservative Nodule Management.
    AJR Am J Roentgenol. 2022 Nov 2. doi: 10.2214/AJR.22.28627.
    PubMed    


  3. GOH V
    Editorial Comment: Artificial Intelligence for Lung Nodules-Progress, but Is It Enough?
    AJR Am J Roentgenol. 2022;219:712.
    PubMed    


  4. LIU JA, Yang IY, Tsai EB
    Artificial Intelligence (AI) for Lung Nodules, From the AJR Special Series on AI Applications.
    AJR Am J Roentgenol. 2022;219:703-712.
    PubMed     Abstract available


    September 2022
  5. HALPENNY D
    Editorial Comment: Improving Lung Screening Specificity-Is There a Need to Use Nodule Volumetrics and Broaden Definitions of Intrapulmonary Lymph Nodes?
    AJR Am J Roentgenol. 2022;219:406.
    PubMed    


  6. HAMMER MM, Hunsaker AR
    Strategies for Reducing False-Positive Screening Results for Intermediate-Size Nodules Evaluated Using Lung-RADS: A Secondary Analysis of National Lung Screening Trial Data.
    AJR Am J Roentgenol. 2022;219:397-405.
    PubMed     Abstract available


    July 2022
  7. ELICKER BM
    Editorial Comment: Stability of Screen-Detected Lung Cancers on Serial CT Examinations.
    AJR Am J Roentgenol. 2022 Jul 6. doi: 10.2214/AJR.22.28179.
    PubMed    


  8. TERRY NLJ
    Editorial Comment: Lung-RADS-Looking Back to Move Forward.
    AJR Am J Roentgenol. 2022;219:65.
    PubMed    


    June 2022
  9. BYRNE SC, Hammer MM
    Malignant Nodules Detected on Lung Cancer Screening CT: Yield of Short-Term Follow-Up CT in Demonstrating Nodule Growth.
    AJR Am J Roentgenol. 2022 Jun 8. doi: 10.2214/AJR.22.27869.
    PubMed     Abstract available


    May 2022
  10. BERGMANN LL, Hobbs S
    Beyond the AJR: The Impact of Screening Population in Lung Cancer Overdiagnosis.
    AJR Am J Roentgenol. 2022 May 25. doi: 10.2214/AJR.22.27970.
    PubMed    


  11. GIERADA DS, Pinsky PF
    Beyond the AJR: Larger and More Diverse Lung Cancer Screening Population Expected After Expansion of Recommended Eligibility Criteria by U.S. Preventive Services Task Force.
    AJR Am J Roentgenol. 2022 May 4:1. doi: 10.2214/AJR.21.27288.
    PubMed    


  12. VANDERLAAN PA
    Percutaneous Lung Biopsy: Point-Fine-Needle Aspiration First.
    AJR Am J Roentgenol. 2022;218:794-795.
    PubMed    


  13. ALEXANDER ES, Ziv E
    Percutaneous Lung Biopsy: Counterpoint-Core Biopsy to Allow for Molecular and Histologic Subtyping.
    AJR Am J Roentgenol. 2022;218:796.
    PubMed    


    April 2022
  14. TAHIR I, Marquardt JP, Mercaldo ND, Bourgouin PP, et al
    Utility of Noncancerous Chest CT Features for Predicting Overall Survival and Noncancer Death in Patients With Stage I Lung Cancer Treated With Stereotactic Body Radiotherapy.
    AJR Am J Roentgenol. 2022 Apr 13. doi: 10.2214/AJR.22.27484.
    PubMed     Abstract available


  15. CHILES C, Osarogiagbon RU
    Beyond the AJR: To Expand the Population-Level Benefit of Lung Cancer Screening, Expand Access to Racially Diverse Populations.
    AJR Am J Roentgenol. 2022 Apr 6:1. doi: 10.2214/AJR.21.27032.
    PubMed    


  16. SUNDARAM B
    Editorial Comment: Promising Role of Volume Doubling Time in Patients With Sarcoma Lung Metastasis.
    AJR Am J Roentgenol. 2022;218:633.
    PubMed    


    March 2022
  17. MURPHY MC, Wrobel MM, Fisher DA, Cahalane AM, et al
    Update on Image-Guided Thermal Lung Ablation: Society Guidelines, Therapeutic Alternatives, and Postablation Imaging Findings.
    AJR Am J Roentgenol. 2022 Mar 23. doi: 10.2214/AJR.21.27099.
    PubMed     Abstract available


  18. SANDLER KL, Deppen SA
    Beyond the AJR: Disparities in Lung Cancer Screening Adherence Persist in the Veterans Health Administration.
    AJR Am J Roentgenol. 2022 Mar 2:1. doi: 10.2214/AJR.21.26852.
    PubMed    


  19. BOURGOUIN PP, Wrobel MM, Mercaldo ND, Murphy MC, et al
    Comparison of Percutaneous Image-Guided Microwave Ablation and Cryoablation for Sarcoma Lung Metastases: A 10-Year Experience.
    AJR Am J Roentgenol. 2022;218:494-504.
    PubMed     Abstract available


    February 2022
  20. ZAFAR N
    Utility of Flat-Bevel Tip Introducer Cannula for Local Pleural Anesthesia During Percutaneous CT-Guided Lung Biopsy.
    AJR Am J Roentgenol. 2022 Feb 2. doi: 10.2214/AJR.21.27306.
    PubMed    


    January 2022
  21. MENDOZA DP, Petranovic M, Som A, Wu MY, et al
    Lung-RADS Category 3 and 4 Nodules on Lung Cancer Screening in Clinical Practice.
    AJR Am J Roentgenol. 2022 Jan 26. doi: 10.2214/AJR.21.27180.
    PubMed     Abstract available


  22. BENNETT P
    Editorial Comment: Evolving Indications for FDG PET/MRI in Lung Cancer.
    AJR Am J Roentgenol. 2022 Jan 5. doi: 10.2214/AJR.21.27246.
    PubMed    


    December 2021
  23. LICHTENBERGER JP 3RD
    Reporting of Clinical Stage for Lung Cancer: Point-Yes, Report an Overall TNM Stage.
    AJR Am J Roentgenol. 2021 Dec 15. doi: 10.2214/AJR.21.27203.
    PubMed    


  24. PEREZ-JOHNSTON R, McDermott S
    Reporting of Clinical Stage For Lung Cancer: Counterpoint-We Are Not There Yet!
    AJR Am J Roentgenol. 2021 Dec 15. doi: 10.2214/AJR.21.27188.
    PubMed    


  25. OHNO Y, Yoshikawa T, Takenaka D, Koyama H, et al
    Small Cell Lung Cancer Staging: Prospective Comparison of Conventional Staging Tests, FDG PET/CT, Whole-Body MRI, and Coregistered FDG PET/MRI.
    AJR Am J Roentgenol. 2021 Dec 8. doi: 10.2214/AJR.21.26868.
    PubMed     Abstract available


    November 2021
  26. HAMMER MM, Byrne SC
    Cancer Risk in Nodules Detected at Follow-up Lung Cancer Screening CT.
    AJR Am J Roentgenol. 2021 Nov 10. doi: 10.2214/AJR.21.26927.
    PubMed     Abstract available


  27. AHN Y, Lee SM, Kim MS, Choi S, et al
    Volume Doubling Times of Pulmonary Metastases in Patients With Bone and Soft Tissue Sarcomas: Associations With Subsequent New Metastases and Survival After Metastasectomy.
    AJR Am J Roentgenol. 2021 Nov 3. doi: 10.2214/AJR.21.26859.
    PubMed     Abstract available


  28. WROBEL MM, Bourgouin PP, Kashani MA, Leppelmann KS, et al
    Active Versus Passive Thaw After Percutaneous Cryoablation of Pulmonary Tumors: Effect on Incidence, Grade, and Onset of Hemoptysis.
    AJR Am J Roentgenol. 2021;217:1153-1163.
    PubMed     Abstract available


    August 2021
  29. BARUAH D
    Editorial Comment: Diagnosing Mediastinal Lymph Node Involvement in Non Small Cell Lung Cancer Noninvasively With Advanced Imaging Markers-Are We There Yet?
    AJR Am J Roentgenol. 2021 Aug 18. doi: 10.2214/AJR.21.26661.
    PubMed    


  30. STEFANIDIS K, Konstantelloy E, Yusuf G, Moser J, et al
    The Evolving Landscape of Lung Cancer Surgical Resection: An Update for Radiologists With Focus on Key Chest CT Findings.
    AJR Am J Roentgenol. 2021 Aug 18. doi: 10.2214/AJR.21.26408.
    PubMed     Abstract available


  31. PARK R, Lee SM, Kim S, Park S, et al
    Learning Curve for CT-Guided Percutaneous Transthoracic Core Needle Biopsy: Retrospective Evaluation Among 17 Thoracic Imaging Fellows at a Tertiary Referral Hospital.
    AJR Am J Roentgenol. 2021 Aug 18. doi: 10.2214/AJR.21.26346.
    PubMed     Abstract available


  32. DENNIE C, Dyer D, Goo JM, Revel MP, et al
    The Global Reading Room: A Likely Infectious Abnormality on Lung Cancer Screening CT.
    AJR Am J Roentgenol. 2021 Aug 4. doi: 10.2214/AJR.21.26617.
    PubMed     Abstract available


    July 2021
  33. NAGANO H, Takumi K, Nakajo M, Fukukura Y, et al
    Dual-Energy CT-Derived Electron Density for Diagnosing Metastatic Mediastinal Lymph Nodes in Non-Small Cell Lung Cancer: Comparison With Conventional CT and FDG PET/CT Findings.
    AJR Am J Roentgenol. 2021 Jul 28. doi: 10.2214/AJR.21.26208.
    PubMed     Abstract available


  34. THAPALIYA S, Gilligan LA, Brady SL, Anton CG, et al
    Comparison of 0.3-mSv CT to Standard-Dose CT for Detection of Lung Nodules in Children and Young Adults With Cancer.
    AJR Am J Roentgenol. 2021 Jul 7. doi: 10.2214/AJR.21.26183.
    PubMed     Abstract available


    June 2021
  35. TSUCHIYA K
    Editorial Comment: New Insights Into the MRI Diagnosis of Brain Metastasis From Lung Cancer.
    AJR Am J Roentgenol. 2021 Jun 2. doi: 10.2214/AJR.21.26288.
    PubMed    


  36. CHELALA L, Hossain R, Kazerooni EA, Christensen JD, et al
    Lung-RADS Version 1.1: Challenges and a Look Ahead, From the AJR Special Series on Radiology Reporting and Data Systems.
    AJR Am J Roentgenol. 2021;216:1411-1422.
    PubMed     Abstract available


  37. ARAUJO-FILHO JAB, Halpenny D, McQuade C, Puthoff G, et al
    Management of Pulmonary Nodules in Oncologic Patients: AJR Expert Panel Narrative Review.
    AJR Am J Roentgenol. 2021;216:1423-1431.
    PubMed     Abstract available


    May 2021
  38. KIM M, Suh CH, Lee SM, Park JE, et al
    Development of Brain Metastases in Patients With Non-Small Cell Lung Cancer and No Brain Metastases at Initial Staging Evaluation: Cumulative Incidence and Risk Factor Analysis.
    AJR Am J Roentgenol. 2021 May 26. doi: 10.2214/AJR.21.25787.
    PubMed     Abstract available


  39. BRUZZI JF
    Editorial Comment: Metabolic Tumor Volume on FDG PET/CT for Predicting Lymphovascular Invasion of Lung Cancer-Proceed With Caution.
    AJR Am J Roentgenol. 2021 May 19. doi: 10.2214/AJR.21.26193.
    PubMed    


  40. KOO CW
    Editorial Comment: Lobectomy Versus Sublobar Resection-How Preoperative CT Features Can Tell You How Much to Resect in Stage IA Non-Small Cell Lung Cancer.
    AJR Am J Roentgenol. 2021 May 19. doi: 10.2214/AJR.21.26175.
    PubMed    


  41. LI C, Tian Y, Shen Y, Wen B, et al
    Utility of Volumetric Metabolic Parameters on Preoperative FDG PET/CT for Predicting Tumor Lymphovascular Invasion in Non-Small Cell Lung Cancer.
    AJR Am J Roentgenol. 2021 May 12. doi: 10.2214/AJR.21.25814.
    PubMed     Abstract available


  42. CHOE J, Kim MY, Yun JK, Lee GD, et al
    Sublobar Resection in Stage IA Non-Small Cell Lung Cancer: Role of Preoperative CT Features in Predicting Pathologic Lymphovascular Invasion and Postoperative Recurrence.
    AJR Am J Roentgenol. 2021 May 12. doi: 10.2214/AJR.21.25618.
    PubMed     Abstract available


  43. HAAS BM
    Editorial Comment: Report Extent of Consolidation and Pulmonary Artery Diameter in Patients With Interstitial Lung Disease Who Are Undergoing an Initial Evaluation of Lung Cancer.
    AJR Am J Roentgenol. 2021 May 5. doi: 10.2214/AJR.21.26099.
    PubMed    


    April 2021
  44. OZAWA Y, Shibamoto Y, Hiroshima M, Nakagawa M, et al
    Preoperative CT Findings for Predicting Acute Exacerbation of Interstitial Pneumonia After Lung Cancer Surgery: A Multicenter Case-Control Study.
    AJR Am J Roentgenol. 2021 Apr 14. doi: 10.2214/AJR.21.25499.
    PubMed     Abstract available


  45. GAN JM, Kikano EG, Smith DA, Bui MT, et al
    Role of Key Guidelines in an Era of Precision Oncology: A Primer for the Radiologist.
    AJR Am J Roentgenol. 2021;216:1112-1125.
    PubMed     Abstract available


    March 2021
  46. CHO JY, Winant AJ, Sohn JH, Vargas SO, et al
    CT Features of Benign Intrapulmonary Lymph Nodes in Pediatric Patients With Known Extrapulmonary Solid Malignancy.
    AJR Am J Roentgenol. 2021 Mar 17:1-6. doi: 10.2214/AJR.20.23363.
    PubMed     Abstract available


    December 2020
  47. SMITH DA, Radzinsky E, Tirumani SH, Guler E, et al
    Findings on Chest CT Performed in the Emergency Department in Patients on Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients.
    AJR Am J Roentgenol. 2020 Dec 9. doi: 10.2214/AJR.20.24758.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: